Contact Hypersensitivity in MHC Class II-Deficient Mice Depends on CD8 T Lymphocytes Primed by Immunostimulating Langerhans Cells  by Bouloc, Anne et al.
Contact Hypersensitivity in MHC Class II-Deficient Mice
Depends on CD8 T Lymphocytes Primed by
Immunostimulating Langerhans Cells
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Studies to determine if CD4F and/or CD8F T cells are
critical for the initiation and propagation of contact
hypersensitivity (CHS) reactions have yielded conflicting
results regarding their roles. We studied the induction
and expression of CHS to trinitrochlorobenzene (TNCB)
using major histocompatibility complex class II-deficient
mice that display normal numbers of CD8F T cells but
lack CD4F T cells. CHS to TNCB, detected as an increase
in ear thickness 24 h after epicutaneous challenge, was
significantly enhanced in major histocompatibility com-
plex class II-deficient mice compared with wild-type
controls. Ear swelling responses in major histocom-
patibility complex class II-deficient mice were decreased
by treatment with anti-CD8 antibody or by injection of
wild-type CD4F T cells. To further characterize mechan-
isms involved in the initiation of CHS responses, pheno-
typical and functional characteristics of both freshly
Contact hypersensitivity (CHS) describes the responseselicited by epicutaneous sensitization and challenge withchemically reactive haptens, small chemically definedmolecules capable of binding directly to soluble andcell associated proteins (Polak, 1980). Since Landsteiner
and Jacobs (1935) first reported the phenomenon of CHS in guinea
pigs, many investigators have elucidated various mechanisms involved
in the generation and expression of CHS to various haptens (Knight
et al, 1985; Macatonia et al, 1987; Kripke et al, 1990; Enk and Katz,
1992, 1995). According to the current paradigm, during the afferent
or sensitization phase, hapten-specific T cells are primed by Langerhans
cells and/or dermal dendritic cells that migrate from the area of antigen
exposure to the skin-draining lymph nodes and present hapten-major
histocompatibility complexes (MHC) to naı¨ve T cells. Subsequently,
the reapplication of the same hapten to skin results in the influx of
hapten-specific T cells that react to the hapten locally, release cytokines,
and attract other inflammatory cells. The resultant swelling can be
measured and reflects the ongoing immune response. CHS is a T cell-
mediated immune response; studies to define the cellular elements that
are responsible have yielded conflicting results. Both CD41 T cells
Manuscript received May 5, 1997; revised February 25, 1998; accepted for
publication March 12, 1998.
Reprint requests to: Dr. Stephen I. Katz, Dermatology Branch, National
Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Abbreviation: CHS, contact hypersensitivity.
1Dr. A. Bouloc is now affiliated with the Department of Dermatology,
Inserm U448, Henri Mondor Hospital AP-HP, 94010 Cre´teil, France.
0022-202X/98/$10.50 · Copyright © 1998 by The Society for Investigative Dermatology, Inc.
44
isolated and cultured Langerhans cells were studied. Like
Langerhans cells from wild-type controls, Langerhans
cells from major histocompatibility complex class II-
deficient mice upregulated B7–1 and B7–2 costimulatory
molecules and enhanced major histocompatibility com-
plex class I expression upon short-term culture. Cultured
Langerhans cells induced a 3.5-fold increase in the stimu-
lation of autologous hapten-specific CD8F T cell prolifer-
ation compared with fresh Langerhans cells. Finally,
TNP-coupled Langerhans cells from major histocom-
patibility complex class II-deficient mice primed naı¨ve
mice to TNCB after transfer. These results demonstrate
that hapten-specific CD81 T cells are sufficient for the
expression of CHS and that CD8 priming does not require
the presence of CD41 T cells or major histocompatibility
complex class II antigen. Key words: CD8 lymphocytes/
MHC class II deficiency. J Invest Dermatol 111:44–49, 1998
and CD81 T cells can recognize haptenated peptides (Martin et al,
1993; Cavani et al, 1995). In vivo and in vitro cell depletion studies
from several laboratories have indicated the importance of CD41 T
cells as the effector cells (Miller and Jenkins, 1985; Gautam et al, 1991),
and others have demonstrated the ability of CD81 T cells to mediate
CHS (Gocinski and Tigelaar, 1990; Bour et al, 1995; Xu et al, 1996).
In this study, we used MHC class II-deficient mice that were
generated by disruption of the MHC class II Ab β gene in embryonic
stem cells. The mice lack cell surface expression of class II molecules
and are depleted of mature CD41 T cells (Grusby et al, 1991). CHS
to TNCB was significantly enhanced in these mice compared with
wild-type controls. Our data indicate that Langerhans cells from MHC
class II-deficient mice undergo functional activation upon short-term
culture, stimulate hapten-specific CD81 T cells in vitro, and can prime
T cells in vivo.
MATERIALS AND METHODS
Animals MHC class II-deficient mice that have a disruption of the Ab β
gene and wild-type controls (C57BL/6) were obtained from the Taconic
Laboratory (Germantown, NY). Mice were used at ages ranging from 8 to
12 wk. All animals were used in accordance with institutional guidelines.
Culture media Cell culture and cell proliferation assays were performed in
RPMI 1640 supplemented with 10% fetal calf serum (Biofluids, Rockville,
MD), 2 mM glutamine, 1% penicillin/streptomycin/fungizone, 10 mM HEPES
buffer, 1% nonessential amino acids, 1 mM sodium pyruvate (all from Life
Technologies, Chagrin Falls, OH), and 5 3 10–5 M β2-mercapto-ethanol
(Sigma, St. Louis, MO). The following monoclonal antibodies were produced
by hybridomas obtained from the American Type Culture Collection (ATCC,
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Rockville, MD) GK1.5 (anti-CD4), 53–6.72 (anti-CD8). Anti-CD45, B7–1,
B7–2, and MHC class I (H-2Kb/H-2Db) antibodies were purchased from
Pharmingen (San Diego, CA).
Chemicals TNCB was obtained from Polysciences (Warrington, PA), TNBS
and fluoroscein isothiocyanate (FITC) were obtained from Sigma.
Preparation of Langerhans cell-enriched fresh epidermal cell
suspensions Epidermal cell suspensions were obtained from the ears of
nontreated mice as previously described (Tamaki et al, 1979). Epidermal cell
suspensions were applied to Lympholyte M density gradients (Cedarlane,
Ontario, Canada) and centrifuged at 800 3 g for 10 min at room temperature.
Interface cells, containing 5–10% Langerhans cells referred to as fresh Langerhans
cells (fresh epidermal cells), were washed extensively in complete medium and
used as antigen-presenting cells in the proliferation assays.
Preparation of Langerhans cell-enriched cultured epidermal cell
suspensions Epidermal cells were suspended at 2 3 106 cells per ml in
complete medium and cultured for 72 h in 25 ml T flasks. Non-adherent cells
were collected by vigorous pipetting and enriched in Langerhans cells by
Lympholyte M gradient centrifugation as described. Such suspensions contained
20–30% Langerhans cells and are referred to as cultured epidermal cells.
Hapten coupling of cells TNP-coupled fresh epidermal cells and TNP-
coupled cultured epidermal cells were obtained by incubating cell suspensions
with 1 mM TNBS for 10 min at 37°C, and were washed extensively in
complete medium. FITC-coupled fresh epidermal cells were obtained by
incubating cell suspensions with 1 mM FITC for 10 min at 37°C, and were
washed extensively in complete medium.
Animal sensitization Mice were sensitized with 100 µl of 3% TNCB
solution (4:1, acetone:olive oil) (both from Sigma) painted onto shaved
abdominal skin. Mice were challenged on day 6 with 20 µl 1% TNCB solution
on the right ear and ear swelling was quantitated with a spring-loaded
micrometer (Mitutuyo, Japan) 24 h after challenge. Mice that were ear-
challenged without prior sensitization served as negative controls. The results
are presented for each group (four mice) as the average difference (6SD) in
ear thickness before and after the challenge.
In some experiments, CD41 T cells or CD81 T cells were depleted in vivo
by intraperitoneal injection of 100 µg of anti-CD4 or anti-CD8 antibodies, on
three consecutive days (–3, –2, –1) prior to sensitization as described (Cobbold
et al, 1985). Cell depletion was assessed by staining for CD4 and CD8 bearing
cells in peripheral blood.
In some experiments, 2 3 106 CD41 T cells from sensitized mice were
injected intravenously 6 d after sensitization immediately prior to challenge.
In others experiments, Langerhans cell-enriched epidermal cell suspensions
(2 3 106) modified with TNBS (1 mM) or with FITC or unmodified control
cells were injected in the footpads (day 0) as a procedure of sensitization.
CD4F and CD8F T cell purification Inguinal, axillary, and brachial lymph
nodes were obtained 1 wk after in vivo sensitization. T cells were enriched by
nylon wool column filtration (Polysciences). CD41 and CD81 T cells were
isolated by negative selection using either rat monoclonal antibodies to CD8
or rat monoclonal antibodies to CD4 followed by incubation with sheep anti-
rat Ig-coated magnetic beads (Dynal, Great Neck, NY) as described (Levin
et al, 1993). Purity of the recovered CD41 or CD81 T cells was ù95% as
determined by staining with anti-CD4 and anti-CD8 antibodies.
Flow cytometry Cells were washed in flow cytometry buffer (PBS, 5% fetal
calf serum, 0.02% sodium azide) and were stained for 30 min at 4°C with
the following antibodies: FITC-anti-CD45, PE-anti-CD45, FITC-anti-B7–1,
FITC-anti-B7–2, PE-anti-MHC class I (H-2Kb/H-2Db) (Pharmingen, San
Diego, CA). The cells were then washed three times with flow cytometry
buffer and analyzed on a Becton Dickinson FACScan.
T cell proliferation assays T cells were plated at 2 3 105 cells per well in
96 flat-bottomed microplates (Costar, Cambridge, MA) and cultured in the
presence of different antigen-presenting cells for 5 d. T cell proliferation was
determined by the incorporation of [3H]thymidine during the last 16 h of
culture using a gas ionization counter (Packard, Meriden, CN). Results are
presented as the mean (6SD) of assays performed in triplicate.
Statistical analyses The significance of differences among groups was exam-
ined by the Student’s t test; p , 0.05 was considered significant.
Figure 1. MHC class II-deficient mice have enhanced CHS reactions
to TNCB in vivo compared with wild-type littermate controls. (A) Wild-
type and MHC class II-deficient mice were sensitized with 100 µl 3% TNCB
on the abdomen and challenged 6 d later on the right ear with 20 µl 1%
TNCB (four mice per group). The results are expressed as the mean of increase
of ear swelling (6SD) 24 h after challenge. The data are representative of two
separate experiments. (B) Wild-type and MHC class II-deficient mice were
sensitized with 100 µl 3% TNCB on the abdomen and challenged 6 d later on
the right ear with 20 µl of different concentrations of TNCB: 1%, 0.5%, 0.1%
(four mice per group). The results are expressed as the mean of increase of ear
swelling (6SD) 24, 48, and 72 h after challenge.
RESULTS
MHC class II-deficient mice have enhanced CHS reactions to
TNCB compared with wild-type littermate controls To test
the role of MHC class II and CD41 T cells in CHS responsiveness,
we examined CHS reactions in wild-type and MHC class II-deficient
mice after sensitization with TNCB. Sensitization of wild-type mice
with 100 µl 3% TNCB led to antigen-specific swelling at the site of
challenge 24 h after painting the ear with 1% TNCB. Mice deficient
in MHC class II regularly showed significantly increased ear swelling
responses (Fig 1A). The kinetics of CHS responses with different
challenging doses are shown in Fig 1(B).
In vivo treatment with anti-CD8 antibody inhibits CHS to
TNCB in MHC class II-deficient mice To confirm that CHS in
MHC class II-deficient mice is due to hapten-specific CD81 T cells,
we injected anti-CD8 monoclonal antibody on three consecutive days
prior to sensitization. This treatment with anti-CD8 antibody resulted
in depletion of CD81 T cells and abrogated CHS responses to TNCB,
indicating that the effector cells in these MHC class II-deficient mice
are the CD81 T cells (Fig 2).
Injection of anti-CD8 antibodies into wild-type controls results
in inhibition of CHS to TNCB and the injection of anti-CD4
antibodies results in enhancement of CHS To investigate the
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Figure 2. In vivo depletion with anti-CD8 monoclonal antibody inhibits
CHS to TNCB in MHC class II-deficient mice. MHC class II-deficient
mice were injected intraperitoneally with 100 µg anti-CD8 monoclonal antibody
(53.6.72) or with rat IgG on three consecutive days (four mice per group).
One day later the animals were sensitized with 100 µl 3% TNCB on the
abdomen. They were then challenged after 6 d on the right ear with 20 µl 1%
TNCB. The results are expressed as the mean of increase of ear swelling (6SD)
24 h after challenge. The data are representative of two separate experiments.
Figure 3. Injection of anti-CD8 monoclonal antibodies into wild-type
controls results in inhibition of CHS to TNCB and the injection of
anti-CD4 antibodies results in enhancement of CHS. Mice were injected
intraperitoneally with 100 µg anti-CD8 (53.6.72) or anti-CD4 monoclonal
antibodies (GK1.5) or with rat IgG on three consecutive days (four mice per
group). One day later the animals were sensitized with 100 µl 3% TNCB on
the abdomen. They were then challenged after 6 d on the right ear with 20 µl
1% TNCB. The results are expressed as the mean of increase of ear swelling
(6SD) 24 h after challenge. The data are representative of two separate
experiments.
role played by CD81 T cells in CHS to TNCB in wild-type mice,
we injected anti-CD8 monoclonal antibody before sensitization. This
resulted in inhibition of CHS to TNCB, showing that CD81 T cells
play a major role in CHS response initiation. The increased CHS to
TNCB in MHC class II-deficient mice and the role of effector cells
played by CD81 T cells suggested that CD41 T cells could be
downregulators of the CHS responses. Consistent with this hypothesis,
depletion of CD41 T cells with anti-CD4 antibody resulted in
enhancement of CHS to TNCB compared with the non-injected
wild-type mice (Fig 3).
Transfer of hapten-specific CD4F T cells from wild-type mice
into MHC class II deficient mice results in diminution of CHS
to TNCB The increased CHS response in MHC class II-deficient
mice and the results of the in vivo depletion of CD41 T cells with
anti-CD4 monoclonal antibody on CHS in wild-type mice suggested
that CD41 T cells downregulate CHS responses to TNCB. Hapten-
specific CD41 T cells were therefore obtained from lymph nodes of
TNCB-painted mice and were injected immediately before challenge
into MHC class II-deficient mice, which had been previously sensitized
on the abdomen with TNCB 3%. The mice exhibited a diminution
Figure 4. Transfer of hapten-specific CD4F T cells from wild-type
mice into MHC class II-deficient mice results in diminution of CHS to
TNCB. MHC class II-deficient mice were sensitized with 100 µl 3% TNCB
on the abdomen. They were injected intravenously with 23106 wild-type
hapten-specific CD41 T cells 6 d later and immediately challenged on the right
ear with 20 µl 1% TNCB (four mice per group). The results are expressed as
the mean of increase of ear swelling (6SD) 24 h after challenge. The data are
representative of two separate experiments.
of CHS responses to TNCB (Fig 4). These data confirm that the
increased CHS observed in MHC class II-deficient mice is due to
their lack of CD41 T cells.
Transfer of hapten-specific CD81 T cells from wild-type mice or
MHC class II-deficient mice in both types of mice did not result in a
diminution of CHS to TNCB (data not shown).
Langerhans cells from MHC class II-deficient mice upregulate
B7–1 and B7–2 costimulatory molecules and exhibit enhanced
MHC class I expression upon short-term culture Using flow
cytometry, we evaluated the ability of MHC class II-deficient Langer-
hans cells to undergo phenotypic change upon short-term culture.
Like MHC class II positive cells from wild-type animals, a subpopulation
of CD451 epidermal cells recovered from MHC class II-deficient mice
showed upregulation of the costimulatory molecules B7–1 and B7–2
after 3 d of culture, as well as enhanced MHC class I expression
(Figs 5, 6). CD45 is expressed on all cells of hematopoietic lineage
and is not expressed on keratinocytes. It is used as a marker of
Langerhans cells; however, it could also be a marker of dendritic
epidermal T cells (DETC). MHC class II-deficient mice have a
distribution of T cells and DETC similar to wild-type controls (data
not shown). There was no upregulation of MHC class I molecules on
the γδ TCR1 population after short-term culture (data not shown),
indicating that it was the Langerhans cells that exhibited the enhanced
MHC class I expression.
Langerhans cells from MHC class II-deficient mice can stimulate
hapten-specific CD8F T cells To determine whether Langerhans
cells from MHC class II-deficient mice can stimulate hapten-specific
CD81 T cells, we cocultured CD81 T cells from MHC class II-
deficient mice with Langerhans cells: either fresh epidermal cells, fresh
epidermal cells coupled with TNBS (TNP-fresh epidermal cells),
cultured epidermal cells, or cultured epidermal cells coupled with
TNBS (TNP-cultured epidermal cells). Both TNP-fresh epidermal
cells and TNP-cultured epidermal cells exhibited antigen-presenting
cell function in the stimulation of hapten-specific CD81 T cells
(Fig 7A). TNP-cultured epidermal cells induced a 3.5-fold increase
in the stimulation of syngenic hapten-specific CD81 T cell proliferation
compared with TNP-fresh epidermal cells, indicating that MHC class
II-deficient Langerhans cells within the epidermal cell population
undergo functional maturation upon short-term culture. Similar results
were obtained in wild-type mice (Fig 7B).
Transfer of TNP-coupled Langerhans cells from MHC class II-
deficient mice can induce CHS to TNCB To investigate whether
TNP-coupled Langerhans cell-enriched epidermal cells from MHC
class II-deficient mice can prime T cells in vivo, we injected TNP-
coupled epidermal cells from MHC class II-deficient mice into naı¨ve
MHC class II-deficient animals. Mice were sensitized with either
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Figure 5. Epidermal cell from MHC class II-deficient mice upregulate B7–1 and B7–2 costimulatory molecules upon short-term culture. Detection
of costimulatory molecules B7–1, B7–2, and CD45 on MHC class II-deficient and wild-type epidermal cell suspensions by two color flow cytometry (data are
plotted as intensities of FITC fluorescence on the x axis versus phycoerythrin fluorescence on the y axis). Epidermal cells were studied in freshly prepared suspensions
(fEC) and after 3 d of culture (cEC).
Figure 6. Epidermal cells from MHC class II-deficient mice exhibit enhanced MHC class I expression upon short-term culture. Detection of MHC
class I antigens and CD45 on MHC class II-deficient and wild-type epidermal cell suspensions by two color flow cytometry (data are plotted as intensities of FITC
fluorescence on the x axis versus phycoerythrin fluorescence on the y axis). Epidermal cells were studied in freshly prepared suspensions (fEC) and after 3 d of
culture (cEC).
100 µl 3% TNCB on the abdomen or with 2 3 106 TNP-epidermal
cells injected in the footpad, and challenged 6 d later on the right ear
with 20 µl 1% TNCB. Hapten-derivatized Langerhans cell-enriched
epidermal cells from MHC class II-deficient mice induce CHS to
TNCB in MHC class II-deficient mice (Fig 8). Uncoupled epidermal
cells or FITC-coupled epidermal cells did not induce any significant
ear swelling. Similar results were obtained when TNP-coupled epi-
dermal cells from MHC class II-deficient mice were injected into
naı¨ve wild-type mice (data not shown). These results indicate that
hapten-derivatized class II-deficient Langerhans cells can prime T
cells in vivo.
DISCUSSION
In this study, we demonstrate that MHC class II-deficient mice have
enhanced CHS reactions to TNCB in vivo compared with wild-type
controls. CD81 T cells appeared to be the effector cells of the CHS
as shown by the results of the in vivo CD8 depletion studies. CD41 T
cells seemed to regulate CHS responses as indicated by the transfer of
hapten-specific CD41 T cells from wild-type controls into MHC class
II deficient mice that resulted in diminution of CHS. These results
confirm experiments reported by Gocinski and Tigelaar (1990), Bour
et al (1995), and Xu et al (1996). Miller and Jenkins (1985) have
previously reported opposite findings. After injection of anti-CD4
antibody, they had observed inhibition of CHS responses. Gocinski
and Tigelaar demonstrated that both CD41 T cells and CD81 T cells
were sufficient to induce CHS to dinitroflurobenzene and that there
were two populations of CD41 T cells, effector and suppressor cells.
Enhanced contact sensitivity reactions to DNFB have been reported
as well in MHC class II-deficient mice (Bour et al, 1995). Since we
began our studies it has been reported by Xu et al that T cell populations
primed by hapten sensitization are distinguished by two polarized
patterns of cytokine production: interferon γ producing effector CD81
T cells and interleukin 4/interleukin 10 producing negative regulatory
CD41 T cells. Altogether these results, consistent with our work,
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Figure 7. Hapten-derivatized epidermal cells from MHC class II-
deficient mice can stimulate (A) hapten-specific CD81 T cells from
MHC class II-deficient mice and (B) hapten-specific T cells from wild-
type mice. (A) In vivo primed TNP-specific CD81 T cells were cocultured
with fresh epidermal cells, TNP-fresh epidermal cells, cultured epidermal cells,
or TNP-cultured epidermal cells. T cell proliferation was determined by the
incorporation of [3H]thymidine (1 µCi per well) during the last 16 h of culture.
Results are presented as the mean (6SD) of proliferation assays performed in
triplicate. The data are representative of two separate experiments. (B) In vivo
primed TNP-specific T cells were cocultured with fresh epidermal cells, TNP-
fresh epidermal cells, cultured epidermal cells, or TNP-cultured epidermal cells.
T cell proliferation was determined by the incorporation of [3H]thymidine (1
µCi per well) during the last 16 h of culture. Results are presented as the mean
(6SD) of proliferation assays performed in triplicate. The data are representative
of two separate experiments.
indicate that CD81 T cells are effector cells in contact hypersensitivity.
It should be noted that contact hypersensitivity differs from delayed
type hypersensitivity to cellular or protein antigens, where only CD41
T cells have been reported to be the effector cells (Cher and
Mosmann, 1987).
Langerhans cell-enriched epidermal cells from MHC class II-deficient
mice also induced CHS to TNCB after in vivo transfer, showing that
antigen-presenting cells can prime CD81 T cells in the absence of
CD41 T helper cells. It had been shown that fetal skin derived class
I1, class II– dendritic cells can stimulate unprimed CD81 T cells (Elbe
et al, 1994). It had also been demonstrated that in CD4 deficient mice
cytotoxic T cell responses could be observed (Buller et al, 1987) and
that the development of CD81 T cells and the cytotoxic functions
were normal (Rahemtulla et al, 1991).
Another issue that is addressed in this study is the role of CD41 T
cells and MHC class II antigens in Langerhans cells activation. Epidermal
Langerhans cells are bone marrow-derived cells and as the primary
antigen-presenting cell population in the skin are responsible for
Figure 8. Hapten-derivatized epidermal cells from MHC class II-
deficient mice induce CHS to TNCB in MHC class II-deficient mice.
Mice were sensitized with either 100 µl 3% TNCB on the abdomen or with
2 3 106 TNP-epidermal cells or FITC-epidermal cells injected in the footpad
and challenged 6 d later on the right ear with 20 µl 1% TNCB (four mice per
group). The results are expressed as the mean of increase of ear swelling (6SD)
24 h after challenge.
initiation of immune responses. They have been implicated as pivotal
antigen-presenting cells in the induction and expression of CHS
(Haftek, 1988). They are the first cells of the skin immune system to
react with a contact allergen, transporting the antigen to the draining
lymph node for presentation to T lymphocytes. Cell surface expression
of MHC molecules and costimulatory molecules are central for their
function (Stingl and Bergstresser, 1995). MHC class I and class II
antigens (Tamaki et al, 1979; Lenz et al, 1989; Sharrow et al, 1994), as
well as costimulatory and adhesion molecules such as ICAM-1 (Tang
and Udey, 1991), LFA-3 (Teunissen et al, 1990), B7–1, and B7–2
(Larsen et al, 1992; Lee et al, 1993), have been identified on the surface
of Langerhans cells. The increased accessory cell activity of cultured
Langerhans cells relative to fresh Langerhans cells is thought to reflect
the increased expression of major histocompatibility complex antigens
and costimulatory molecules. Here we show that, except from lacking
MHC class II molecules, Langerhans cells from MHC class II-
deficient mice had otherwise normal phenotypic characteristics. They
upregulated B7–1 and B7–2 costimulatory molecules and exhibited
enhanced MHC class I expression and increased antigen-presenting
cell activity after short-term culture. The full expression of CHS is
usually thought to require that epidermal Langerhans cells present
antigen in the context of MHC class II molecules to specifically
sensitized T lymphocytes. It has been suggested that the CD41 T cell-
derived cytokines may be essential for terminal differentiation of
Langerhans cells into lymphoid dendritic cells (Kitajima et al, 1996).
Our data indicate that Langerhans cells from MHC class II-deficient
mice had normal functional characteristics in vivo as well as in vitro.
One possibility is that terminal differentiation of Langerhans cells in vivo
is T cell independant. Another possibility is that both CD81 T cells
and CD41 T cells may induce these important functional changes.
Additional experiments will be required to differentiate between these
two alternatives.
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